CEO and CFO Share Purchases

RNS Number : 3905V
Tissue Regenix Group PLC
05 April 2023
 

Tissue Regenix Group plc

('Tissue Regenix' or the 'Company')

 

CEO and CFO Share Purchases

 

Tissue Regenix (AIM: TRX), the regenerative medical device company, announces that on 4 April 2023, Daniel Lee, Chief Executive Officer, and David Cocke, Chief Financial Officer each purchased 1,428,570 of the Company's ordinary shares of 0.1p each ("Ordinary Shares").

 

Name

Title

Number of Ordinary Shares purchased

Resulting beneficial interest in the Company's Ordinary Shares

Percentage of Company's Total Voting Rights

Daniel Lee

Chief Executive Officer

1,428,570

8,690,770

0.12%

David Cocke

Chief Financial Officer

1,428,570

7,120,570

0.10%

 

For more information:

 

Tissue Regenix Group plc

www.tissueregenix.com

David Cocke, Chief Financial Officer

Via Walbrook PR



finnCap Ltd (Nominated Adviser and Broker) 


Emily Watts/Geoff Nash/George Dollemore - Corporate Finance


Nigel Birks/Harriet Ward - ECM


 


Walbrook PR (Financial PR & IR)

Tel: +44(0)20 7933 8780

Alice Woodings / Lianne Applegarth

TissueRegenix@walbrookpr.com

 

 

 

About Tissue Regenix (www.tissueregenix.com)

Tissue Regenix is a leading medical device company in the field of regenerative medicine. The Company's patented decellularisation technology ('dCELL®') removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or damaged body structures. Current applications address many critical clinical needs in sports medicine, foot and ankle and wound care.

 

In August 2017, Tissue Regenix acquired CellRight Technologies®, a biotech company that specialises in regenerative medicine and is dedicated to the development of high quality, innovative tissue scaffolds, which can enhance healing opportunities in defects created by trauma and disease. CellRight®'s human tissue products may be used in spine, trauma, general orthopaedic, dental and ophthalmological surgical procedures.

 

 

 

 

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Daniel Lee

 

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Chief Executive Officer

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Tissue Regenix Group plc

b)

 

LEI

 

 

 213800PNOD5UHQUFJI36

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares of 0.1p each



Identification code

GB00B5SGVL29



b)

 

Nature of the transaction

 

 

Purchase

c)

 

Price(s) and volume(s)







Price(s)

Volume(s)




0.5700p

500,000




0.5650p

928,570







d)

 

Aggregated information




- Aggregated volume

1,428,570



- Price

£8,096.42



e)

 

Date of the transaction

 

 

4 April 2023

f)

 

Place of the transaction

 

 

London Stock Exchange, AIM Market

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

David Cocke

 

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Chief Financial Officer

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Tissue Regenix Group plc

b)

 

LEI

 

 

 213800PNOD5UHQUFJI36

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares of 0.1p each



Identification code

GB00B5SGVL29



b)

 

Nature of the transaction

 

 

Purchase

c)

 

Price(s) and volume(s)







Price(s)

Volume(s)




0.5700p

500,000




0.5650p

928,570







d)

 

Aggregated information




- Aggregated volume

1,428,570



- Price

£8,096.42



e)

 

Date of the transaction

 

 

4 April 2023

f)

 

Place of the transaction

 

 

London Stock Exchange, AIM Market

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHKZGGDRDKGFZM
UK 100

Latest directors dealings